<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2503257166
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Ebglyss
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Lebrikizumab
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in the refrigerator at a temperature of (2-8) degrees Celsius, keep in the package to protect from light, do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4413.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Eli Lilly and Company, Clinton Laboratories" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Eli Lilly and Company, Clinton Laboratories
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Eli Lilly and Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EBGLYSS injection is a sterile, preservative free, clear, colorless to slightly yellow solution, free of visible particles, for subcutaneous use available as 250&nbsp;mg of lebrikizumab in a 2&nbsp;mL single-dose prefilled pen or a single-dose prefilled syringe with needle shield.</p><p>EBGLYSS is a prescription medicine used to treat adults and adolescents 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. EBGLYSS can be used with or without topical corticosteroids. EBGLYSS works by blocking a protein that contributes to inflammation that plays a major role in atopic dermatitis. The safety and effectiveness of EBGLYSS in adolescents with atopic dermatitis who are 12 years of age or older and weigh at least 88 pounds (40 kg) has been established. It is not known if EBGLYSS is safe and effective in adolescents with atopic dermatitis who weigh less than 88 pounds (40 kg) or in children under 12 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Before you use EBGLYSS, tell your healthcare provider about all your medical conditions, including if you: </strong></p><p>&bull; are scheduled to receive any vaccinations. You should not receive a &ldquo;live vaccine&rdquo; if you are treated with EBGLYSS.</p><p>&bull; are pregnant or plan to become pregnant. It is not known if EBGLYSS will harm your unborn baby.</p><p>&bull; are breastfeeding or plan to breastfeed. It is not known if EBGLYSS passes into your breast milk.</p><p><strong>Tell your healthcare provider about all the medicines you take, </strong>including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before using Ebglyss.</p><p>Every time you get a new pack of Ebglyss, it is important that you note down the date and the batch number (which is on the packaging after &ldquo;Lot&rdquo;) and keep this information in a safe place.</p><p><u>Allergic reactions </u></p><p>Very rarely, this medicine can cause allergic (hypersensitivity) reactions. These reactions can occur shortly after you take Ebglyss, but also may happen later. If you notice symptoms of an allergic reaction, you should stop using this medicine and contact your doctor or get medical help immediately. Signs of an allergic reaction include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, mouth, and tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling lightheaded (because of low blood pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives, itching and skin rash</p><p><u>Eye problems </u></p><p>Talk to your doctor if you have any new or worsening eye problems, including redness and discomfort in the eye, eye pain or changes in vision.</p><p><u>Vaccination </u></p><p>Talk to your doctor regarding your current vaccinations plan. See section &ldquo;Other medicines and Ebglyss&rdquo;.</p><p><strong>Children and adolescents </strong></p><p>This medicine should not be used in children with atopic dermatitis below the age of 12 or adolescents 12 to 17 years of age and weighing less than 40 kg because it has not been tested in this age group.</p><p><strong>Other medicines and Ebglyss </strong></p><p>Tell your doctor or pharmacist:</p><p>-&nbsp;&nbsp;&nbsp; if you are using, have recently used or might use any other medicines.</p><p>-&nbsp;&nbsp;&nbsp; if you have recently had a vaccination or plan to have one. You should not be given certain types of vaccines (live vaccines) while using Ebglyss.</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>The effects of this medicine in pregnant women are not known. It is better to avoid the use of Ebglyss during pregnancy unless your doctor advises you to use it.</p><p>It is not known whether lebrikizumab can pass into breast milk. If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine. You and your doctor should decide if you will breast-feed or use Ebglyss. You should not do both.</p><p><strong>Driving and using machines </strong></p><p>Ebglyss is unlikely to influence your ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Recommended Dosage </strong></p><p>Adults and Adolescents (12 years of age and older who weigh at least 40 kg)</p><p>The recommended dosage of EBGLYSS is an initial dose of 500&nbsp;mg (two 250&nbsp;mg injections) injected subcutaneously at Week 0 and Week 2, followed by 250&nbsp;mg every two weeks until Week 16 or later, when adequate clinical response is achieved. The maintenance dose is 250&nbsp;mg every four weeks; some patients may maintain adequate clinical response with a dose of 250&nbsp;mg every eight weeks.</p><p><strong>Missed Dose </strong></p><p>If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>See the Instructions for Use that comes with EBGLYSS about how to prepare and inject EBGLYSS and how to properly store and throw away (dispose of) used EBGLYSS prefilled pens. </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use EBGLYSS exactly as prescribed by your healthcare provider.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EBGLYSS comes as a single-dose prefilled pen.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EBGLYSS is given by injection under the skin (subcutaneous injection).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your healthcare provider decides that you or a caregiver can give the injections of EBGLYSS, you or a caregiver should receive training on the right way to prepare and inject EBGLYSS. Do not try to inject EBGLYSS until you have been shown the right way by your healthcare provider. In people under the age of 18 years, EBGLYSS should be given by an adult.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inject EBGLYSS in your stomach area (abdomen) or thigh, or have a caregiver inject EBGLYSS in the back of your upper arm.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose, inject the missed dose as soon as possible, then continue your next dose at your regular scheduled time.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you inject too much EBGLYSS (overdose), get medical help or contact The National Pharmacovigilance Center. Your healthcare provider may prescribe other medicines to use with EBGLYSS. Use the other prescribed medicines exactly as your healthcare provider tells you to.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have questions about when you should use EBGLYSS, ask your healthcare provider.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The most common side effects of EBGLYSS include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye and eyelid inflammation, including redness, swelling, and itching</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site reactions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shingles (herpes zoster)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High count of certain white blood cells</p><p><strong>These are not all of the possible side effects of EBGLYSS.</strong> Call your doctor for medical advice about side effects. You may report side effects to The National Pharmacovigilance Center</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EBGLYSS is sterile and preservative-free.</p><p>Store refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) in the original carton to protect from light.</p><p>If necessary, EBGLYSS may be kept at room temperature below 30&deg;C (86&deg;F) for up to 7 days in the original carton. Throw away EBGLYSS if not used within 7 days at room temperature.</p><p>Do not freeze. Do not use EBGLYSS if it has been frozen.</p><p>Do not shake.</p><p>Discard the EBGLYSS single-dose prefilled pen after use in a puncture-resistant container.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use EBGLYSS for a condition for which it is not prescribed. Do not give EBGLYSS to other people, even if they have the same symptoms you have. It may harm them.</p><p>You can ask your pharmacist of healthcare provider for information about EBGLYSS that is written for health professionals.</p><p><strong>What are the ingredients in EBGLYSS? </strong></p><p><strong>Active ingredient:</strong> lebrikizumab</p><p><strong>Inactive ingredient:</strong> glacial acetic acid, L-histidine, polysorbate 20, sucrose, and Water for Injection, USP.</p><p>EBGLYSS prefilled pen are not made with natural rubber latex.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What EBGLYSS looks like and contents of the pack 
EBGLYSS (lebrikizumab) injection is a sterile, preservative free, clear, colorless to slightly yellow solution, free of visible particles, available in a single-dose prefilled pen. Each prefilled pen designed to deliver 250 mg of EBGLYSS in 2 mL.
EBGLYSS is supplied as:
	Pack Size
Prefilled Pen
250 mg/2 mL single-dose	Carton of 1
250 mg/2 mL single-dose	Carton of 2

Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Eli Lilly and Company, Lilly Corporate Centre, Indianapolis, IN 46285, USA</p><p><strong>Manufacturer</strong></p><p>Eli Lilly and Company, Lilly Corporate Centre, Indianapolis, IN 46285, USA</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Eli Lilly &amp; Company &ndash; Saudi Arabia</p><p>PO Box 92120</p><p>16th Floor, Building Number 3074,</p><p>Tower B, Olaya Towers</p><p>Prince Mohamed Ibn Abdulaziz Street</p><p>Olaya, Riyadh</p><p>Kingdom of Saudi Arabia</p><p>Direct Line:&nbsp; +966 11 461 7800, +966 11 4617850&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Fax: +966 11 217 9900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was issued in August 2023
Version 1 

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إبجليس للحقن هو محلول معقّم وخالٍ من المواد الحافظة وصافٍ وعديم اللون إلى أصفر بعض الشيء وخالٍ من الجزيئات المرئيّة، للاستعمال تحت الجلد، متوافر كـ 250 ملغ من ليبريكيزوماب في قلم معبّأ مسبقًا بجرعة واحدة أو محقنة معبّأة مسبقًا&nbsp; بجرعة واحدة مع غطاء واقٍ للإبرة من 2 مل.</p><p dir="RTL">ابجليس هو دواء يُصرف بناء على وصفة طبيّة يُستخدم لعلاج البالغين والمراهقين الذين تبلغ أعمارهم 12 عامًا وما فوق المصابين بالتهاب الجلد التأتبي المتوسط إلى الشديد (الإكزيما) الذي لا يتم التحكّم به جيدًا من خلال العلاجات الموصوفة المستخدمة على الجلد (موضعيًا)، أو الذين لا يمكنهم استخدام العلاجات الموضعيّة. يمكن استخدام ابجليس مع الستيرويدات القشريّة الموضعيّة أو بدونها. يعمل ابجليس عن طريق منع بروتين يساهم في الالتهاب الذي يلعب دورًا رئيسيًا في التهاب الجلد التأتبي. لقد تمّ إثبات سلامة ابجليس وفعاليّته لدى المراهقين المصابين بالتهاب الجلد التأتبي الذين تبلغ أعمارهم 12 عامًا أو أكثر ويزنون 88 رطلاً (40 كلغ) على الأقلّ. من غير المعروف ما إذا كان ابجليس آمنًا وفعّالًا لدى المراهقين المصابين بالتهاب الجلد التأتبي الذين يقلّ وزنهم عن 88 رطلاً (40 كلغ) أو لدى الأطفال دون سنّ 12 عامًا.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>قبل أن تستعمل ابجليس، أعلم مقدّم الرعاية الصحيّة الخاص بك عن جميع مشاكلك الصحيّة، بما في ذلك إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان من المقرر أن تتلقى أيّ لقاحات. يجب ألا تتلقّى &quot;لقاحًا حيًا&quot; إذا كنت تُعالج بابجليس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ حاملاً أو تنوين الحمل. من غير المعروف ما إذا كان ابجليس سيؤذي جنينك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ تُرضعين طفلك أو تنوين إرضاعه. من غير المعروف ما إذا كان ابجليس يمرّ في حليب الثدي.</p><p dir="RTL"><strong>أعلم مقدّم الرعاية الصحيّة الخاص بك عن كلّ الأدوية التي تأخذها،</strong> بما في ذلك الأدوية التي تُصرف بناء على وصفة طبيّة وبدون وصفة طبيّة والفيتامينات والمكمّلات العشبيّة.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدّث إلى طبيبك أو الصيدليّ أو الممرّضة قبل استعمال ابجليس.</p><p dir="RTL">في كلّ مرّة تحصل فيها على علبة جديدة من ابجليس، من المهمّ أن تدوّن التاريخ ورقم الدفعة (الموجود على العبوة بعد &quot;الدفعة&quot; &ldquo;Lot&rdquo;) والاحتفاظ بهذه المعلومات في مكان آمن.</p><p dir="RTL"><u>ردود فعل تحسسيّة </u></p><p dir="RTL">في حالات نادرة جدًا، يمكن أن يسبّب هذا الدواء ردود فعل تحسسيّة (فرط حساسية). يمكن أن تحدث ردود الفعل هذه بعد وقت قصير من تناول ابجليس، ولكنها قد تحدث أيضًا لاحقًا. إذا لاحظت أعراض رد فعل تحسسي، يجب عليك التوقف عن استعمال هذا الدواء والاتصال بطبيبك أو الحصول على مساعدة طبيّة على الفور. تشمل علامات رد الفعل التحسسي ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp; مشاكل في التنفّس</p><p dir="RTL">&middot;&nbsp;&nbsp; تورّم الوجه والفم واللسان</p><p dir="RTL">&middot;&nbsp;&nbsp; إغماء</p><p dir="RTL">&middot;&nbsp;&nbsp; دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp; شعور بالدوار (بسبب انخفاض ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp; شرى وحكة وطفح جلدي</p><p dir="RTL"><u>مشاكل العين</u></p><p dir="RTL">تحدّث إلى طبيبك إذا عانيت من أيّ مشاكل جديدة أو متفاقمة في العين، بما في ذلك الاحمرار والانزعاج في العين، أو الألم في العين أو تغييرات في الرؤية.</p><p dir="RTL"><u>التلقيح</u></p><p dir="RTL">تحدّث مع طبيبك بخصوص خطة التلقيح الحاليّة الخاصة بك. انظر قسم &quot;أدوية أخرى وابجليس&quot;.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينبغي استعمال هذا الدواء لدى الأطفال المصابين بالتهاب الجلد التأتبي الذين تقلّ أعمارهم عن 12 عامًا أو لدى المراهقين الذين تتراوح أعمارهم بين 12 إلى 17 عامًا ويزنون أقلّ من 40 كجم لأنّه لم يتمّ اختباره في الفئة العمريّة هذه.<strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى وابجليس</strong></p><p dir="RTL">أعلم طبيبك أو الصيدلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستعمل أو استعملت مؤخرًا أو قد تستعمل أيّ أدوية أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت لقاحًا مؤخّرًا أو تنوي تلقّي لقاح. لا ينبغي أن تتلقّى أنواعًا معيّنة من اللقاحات (اللقاحات الحيّة) أثناء استعمال ابجليس.<strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعيّة والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة، أو تعتقدين أنك حامل أو تنوين إنجاب طفل، استشيري طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">إنّ آثار هذا الدواء على النساء الحوامل غير معروفة. لذلك، من الأفضل تجنّب استعمال إبجليس أثناء الحمل إلا إذا نصحك طبيبك باستعماله.</p><p dir="RTL">من غير المعروف ما إذا كان يمكن أن ينتقل ليبريكيزوماب إلى حليب الثدي. إذا كنت مرضعة أو تخططين للرضاعة الطبيعيّة، تحدثي مع طبيبك قبل استعمال هذا الدواء. يجب عليكما أنت وطبيبك أن تقررا ما إذا كنت ستُرضعين طفلك أو ستستعملين إبجليس. لا ينبغي بكِ القيام بالأمرين معًا.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثّر إبجليس على قدرتك على القيادة واستخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة الموصى بها</strong></p><p dir="RTL"><u>البالغون والمراهقون (12 سنة وما فوق والذين لا يقلّ وزنهم عن 40 كلغ)</u></p><p dir="RTL">يبلغ مقدار الجرعة الموصى بها من إبجليس جرعة أوليّة من 500 ملغ (حقنتان من 250 ملغ) يتمّ حقنها تحت الجلد في الأسبوع 0 والأسبوع 2، تليها جرعة من 250 ملغ كلّ أسبوعين حتى الأسبوع 16 أو ما بعده، عندما يتمّ تحقيق استجابة سريريّة كافية. تبلغ جرعة المداومة 250 ملغ كلّ أربعة أسابيع. قد يحافظ بعض المرضى على استجابة سريريّة كافية مع جرعة من 250 ملغ كلّ ثمانية أسابيع.<strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة الفائتة</strong></p><p dir="RTL">في حالة تفويت جرعة، قم بإعطاء الجرعة في أسرع وقت ممكن. بعد ذلك، استأنف إعطاء الجرعات في الوقت المقرّر العادي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>راجع تعليمات الاستخدام التي تأتي مع ابجليس حول كيفيّة تحضير ابجليس وحقنه وكيفيّة تخزين أقلام ابجليس المعبّأة مسبقًا ورميها (التخلّص منها) بشكل صحيح.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استعمل ابجليس تمامًا على النحو الذي يصفه مقدّم الرعاية الصحيّة الخاص بك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يأتي ابجليس على شكل قلم معبّأ مسبقًا بجرعة واحدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُعطى ابجليس عن طريق الحقن تحت الجلد (حقن تحت الجلد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا قرّر مقدّم الرعاية الصحيّة الخاص بك أنّه يمكنك أنت أو مقدّم رعاية إعطاء حقن ابجليس، يجب أن تتلقّى أنت أو مقدّم الرعاية تدريباً على الطريقة الصحيحة لتحضير ابجليس وحقنه. لا تحاول حقن ابجليس قبل أن يعلّمك مقدّم الرعاية الصحيّة الطريقة الصحيحة. لدى الأشخاص الذين تقلّ أعمارهم عن 18 عامًا، يجب أن يُعطي شخص بالغ ابجليس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احقن ابجليس في منطقة المعدة (البطن) أو الفخذ، أو اجعل مقدّم الرعاية يحقن ابجليس في الجزء الخلفي من أعلى ذراعك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فوّت جرعة، احقن الجرعة الفائتة في أقرب وقت ممكن ومن ثمّ خذ جرعتك التالية في الوقت المعتاد المحدد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حقنت كميّة كبيرة من ابجليس (جرعة زائدة)، أطلب مساعدة طبيّة أو اتصل بخبير في المركز الوطني للتيقظ والسلامة الدوائية على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يصف مقدّم الرعاية الصحيّة الخاص بك أدوية أخرى لاستعمالها مع ابجليس. استعمل الأدوية الموصوفة الأخرى حسب تعليمات مقدّم الرعاية الصحيّة الخاص بك تمامًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك أسئلة حول متى يجب عليك استعمال ابجليس، اسأل مقدّم الرعاية الصحيّة الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتضمّن الآثار الجانبيّة الشائعة لابجليس ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين والجفن، بما في ذلك الاحمرار والتورّم والحكّة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات موقع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القوباء المنطقية (الهربس النطاقي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع عدد بعض خلايا الدم البيضاء</p><p dir="RTL"><strong>هذه ليست جميع الآثار الجانبيّة المحتملة لابجليس.</strong> اتصل بطبيبك للحصول على مشورة طبيّة حول الآثار الجانبيّة. يمكنك إبلاغ المركز الوطني للتيقظ والسلامة الدوائية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ابجليس معقّم وخالٍ من المواد الحافظة.</p><p dir="RTL">يُخزّن في الثلاجة في حرارة تترواح بين درجتين مئويّتين و8 درجات مئوية (36 درجة فهرنهايت إلى 46 درجة فهرنهايت) في علبة الكرتون الأصليّة لحمايته من الضوء.</p><p dir="RTL">إذا لزم الأمر، يمكن تخزين ابجليس في درجة حرارة الغرفة دون 30 درجة مئوية (86 درجة فهرنهايت) لمدّة تصل إلى 7 أيام في علبة الكرتون الأصليّة. يجب التخلّص من ابجليس إذا لم يتمّ استخدامه خلال 7 أيام في درجة حرارة الغرفة.</p><p dir="RTL">لا ينبغي تجميده. لا ينبغي استعمال ابجليس إذا تمّ تجميده.</p><p dir="RTL">لا ينبغي رجّه.</p><p dir="RTL">تخلّص من قلم ابجليس المعبّأ مسبقًا بجرعة واحدة بعد الاستعمال في حاوية مقاومة للثقب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">توصف الأدوية أحيانًا لأغراض أخرى غير تلك المذكورة في نشرة معلومات المريض. لا تستعمل ابجليس لحالة غير موصوف لها. لا تعطِ ابجليس لأشخاص آخرين، حتى لو كان لديهم الأعراض ذاتها التي لديك. فقد يؤذيهم.</p><p dir="RTL">يمكنك أن تطلب من الصيدلي أو من مقدّم الرعاية الصحيّة تزويدك بمعلومات حول ابجليس مكتوبة للأخصّائينن الصحيين.</p><p dir="RTL"><strong>ما هي مكوّنات ابجليس؟</strong></p><p dir="RTL"><strong>المادة الفعالة</strong>: ليبريكيزوماب</p><p dir="RTL"><strong>المكوّنات غير الفعالة</strong>: حمض الخليك الجليدي، ل- هيستيدين، بولي سوربات 20، سكروز، وماء للحقن، دستور الأدوية الأمريكي.</p><p dir="RTL">قلم ابجليس المعبّأ مسبقًا غير مصنوع من المطاط الطبيعي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ابجليس (ليبريكيزوماب) للحقن هو محلول معقّم وخالٍ من المواد الحافظة وصافٍ وعديم اللون إلى أصفر بعض الشيء وخالٍ من الجزيئات المرئيّة، يأتي على شكل قلم معبّأ مسبقًا بجرعة واحدة. تمّ تصميم كل قلم معبّأ مسبقًا لإعطاء 250 ملغ من ابجليس في 2 مل.&nbsp;</p><p dir="RTL">يأتي ابجليس على شكل:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">حجم العبوة</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>قلم معبّأ مسبقًا</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">جرعة واحدة من 250 ملغ/2 مل</p></td><td style="vertical-align:top"><p dir="RTL">علبة كرتون فيها قلم واحد</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">جرعة واحدة من 250 ملغ/2 مل</p></td><td style="vertical-align:top"><p dir="RTL">علبة كرتون فيها قلمان</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تكون جميع أحجام العلب متوافرة في بلدك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل رخصة التسويق</strong></p><p dir="RTL">شركة إيلي ليلي وشركاه. مركز الشركة ليلي إنديانابوليس، ولاية إنديانا 46285، الولايات المتّحدة الأمريكية.<strong>&nbsp;</strong></p><p dir="RTL"><strong>المصنع وموقع التغليف</strong> <strong>الأولي والفسح</strong></p><p dir="RTL">شركة إيلي ليلي وشركاه. مركز الشركة ليلي إنديانابوليس، ولاية إنديانا 46285، الولايات المتّحدة الأمريكية.</p><p dir="RTL"><strong>&nbsp;</strong>للحصول على أيّ معلومات تتعلّق بهذا الدواء، يُرجى الاتصال بالممثل المحلّي لحامل ترخيص التسويق:</p><p dir="RTL">شركة إيلي ليلي آند كومباني- المملكة العربية السعودية<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-begin'></span> </span><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'>VAULT_ND_b18c77b7-9813-40e4-b864-792e5b611e9c \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;font-family:"Arial Unicode MS",sans-serif;color:black'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=AR-SA style='mso-bidi-font-size:11.0pt;
font-family:"Arial Unicode MS",sans-serif;color:black'><span style='mso-element:
field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">ص.ب92120 :<!--[if supportFields]><span lang=EN-GB dir=LTR
style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_153d007a-eee2-4f92-ac78-ae191f145d5c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">الطابق16 ، مبنى رقم 3074<!--[if supportFields]><span lang=EN-GB dir=LTR
style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_27ad7280-6e63-44b0-8626-e15f1c503864 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">برج ب، أبراج العُليَّا<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-begin'></span> </span><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'>VAULT_ND_10c8a9ae-c676-4e2a-9dc9-29e22fc8b049 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;font-family:"Arial Unicode MS",sans-serif;color:black'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=AR-SA style='mso-bidi-font-size:11.0pt;
font-family:"Arial Unicode MS",sans-serif;color:black'><span style='mso-element:
field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">شارع الأمير محمد بن عبد العزيز<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-begin'></span> </span><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'>VAULT_ND_9b83105d-c1d4-4870-b033-ac9d2154a09f \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;font-family:"Arial Unicode MS",sans-serif;color:black'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=AR-SA style='mso-bidi-font-size:11.0pt;
font-family:"Arial Unicode MS",sans-serif;color:black'><span style='mso-element:
field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">العُليَّا، الرياض<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-begin'></span> </span><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'>VAULT_ND_4b8588e4-c21e-41f5-b793-d009e6760e33 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;font-family:"Arial Unicode MS",sans-serif;color:black'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=AR-SA style='mso-bidi-font-size:11.0pt;
font-family:"Arial Unicode MS",sans-serif;color:black'><span style='mso-element:
field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">المملكة العربية السعودية<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-begin'></span> </span><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'>VAULT_ND_56a07d1f-c031-48d6-8318-9a57122679bb \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;font-family:"Arial Unicode MS",sans-serif;color:black'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=AR-SA style='mso-bidi-font-size:11.0pt;
font-family:"Arial Unicode MS",sans-serif;color:black'><span style='mso-element:
field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">الخط المباشر: 966114617850+،&nbsp; 966114617800+<!--[if supportFields]><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">الفاكس&nbsp;: 966112179900+<!--[if supportFields]><span
lang=EN-GB dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial Unicode MS",sans-serif;
color:black'><span style='mso-element:field-end'></span></span><![endif]--></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أُعدّت النشرة المريض هذه في أوغسطس ٢٠٢٣
النسخة 1 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EBGLYSS 250 mg/2 mL; injection, for subcutaneous use. 
EBGLYSS is a sterile, preservative free, clear, colorless to slightly yellow solution, free of visible particles.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.1	General description
Lebrikizumab is a recombinant immunoglobulin G4 (IgG4) monoclonal antibody (MAb) that binds with high affinity to interleukin (IL)-13 and inhibits IL-13 signaling. Lebrikizumab is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.

2.2	Qualitative and quantitative composition

EBGLYSS injection is a sterile, preservative free, clear, colorless to slightly yellow solution, free of visible particles, for subcutaneous use available as 250 mg of lebrikizumab in a 2 mL single-dose prefilled pen. The EBGLYSS prefilled pen is not made with natural rubber latex.

Each prefilled pen is manufactured to deliver a single dose of 250 mg lebrikizumab in 2 mL solution which also contains glacial acetic acid (1.8 mg), L-histidine (6.2 mg), polysorbate 20 (0.6 mg), sucrose (119.6 mg) and Water for Injection, USP. The pH is 5.4 – 6.0.

For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EBGLYSS is a sterile, preservative free, clear, colorless to slightly yellow solution, free of visible particles; available as follows:
•	Injection: 250 mg/2 mL in a single-dose prefilled pen

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Atopic Dermatitis</strong><!--[if supportFields]><b><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-US'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_59b57e5c-454c-47b8-bccb-ea4bd4eecc59 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-US'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>EBGLYSS is indicated for the treatment of adult and adolescent patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vaccination Prior to Administration of EBGLYSS<!--[if supportFields]><span style='font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f93f9d98-3c69-4f35-a998-0cc886f85c21 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Consider completing all age-appropriate immunizations according to current immunization guidelines <em>[see Special warnings and precautions for use (4.4)].</em></p><p>Recommended Dosage<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_405f34b7-155f-4c36-b711-eb88274a1738 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Adults and Adolescents (12 years of age and older who weigh at least 40 kg)</p><p>The recommended dosage of EBGLYSS is an initial dose of 500&nbsp;mg (two 250&nbsp;mg injections) injected subcutaneously at Week 0 and Week 2, followed by 250&nbsp;mg every two weeks until Week 16 or later, when adequate clinical response is achieved <em>[see Pharmacodynamic properties (5.1)]</em>. The maintenance dose is 250&nbsp;mg every four weeks <em>[see Pharmacodynamic properties (5.1)]</em>; some patients may maintain adequate clinical response with a dose of 250&nbsp;mg every eight weeks <em>[see Pharmacokinetic properties (5.2)]</em>.</p><p>Concomitant Topical Therapies<!--[if supportFields]><span style='font-size:11.0pt;
mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_9acd5563-6c9f-45b3-8f8d-c5ee5c0b431a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-bidi-font-weight:bold'><span style='mso-element:
field-end'></span></span><![endif]--></p><p>Lebrikizumab can be used with or without topical corticosteroids (TCSs) or topical calcineurin inhibitors (TCIs).</p><p>Important Administration Instructions<!--[if supportFields]><span style='font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_eba84e2a-7017-4c45-8660-f23638714c5a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; EBGLYSS is for subcutaneous administration.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; EBGLYSS is intended for use under the guidance of a healthcare professional. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of EBGLYSS according to the &ldquo;Instructions for Use&rdquo;, included with the packaged product. Adult patients may self-inject, or caregivers may give EBGLYSS after training in subcutaneous injection technique. For adolescent patients, caregivers may give injections after training in subcutaneous injection technique.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Sites for injection include the abdomen, thigh, and back of the upper arm. Administration of EBGLYSS in the back of the upper arm may be performed by a caregiver or healthcare provider (<em>see Instructions for Use)</em>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Instruct patients not to inject in the exact same spot every time. Do not inject into areas where the skin is tender, bruised, red, hard, or in an area of skin that is affected by atopic dermatitis or skin lesions.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Before injection, remove EBGLYSS prefilled pen from the refrigerator and leave at room temperature for 45 minutes without removing the needle cap. Do not warm by using a heat source such as hot water or microwave.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Inspect EBGLYSS visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the liquid contains visible particles, is discolored or cloudy <em>[see Pharmaceutical Form (3) and Nature and contents of container (6.5)]</em>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; EBGLYSS does not contain preservatives.</p><p>Missed Dose<!--[if supportFields]><span style='font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3cf8bfb2-32ef-4e55-8aab-cb0a6eab6b78 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.</p><p>Method of administration<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_729acdf9-665f-40cc-84d1-41468149cad7 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>injection, for subcutaneous use<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_bc7fa0b8-a6e3-4b0d-b087-aa28723bea0c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EBGLYSS is contraindicated in patients with prior serious hypersensitivity to lebrikizumab or any of its excipients [see Special warnings and precautions for use (4.4)].
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Traceability</em><!--[if supportFields]><span
style='font-size:11.0pt;mso-fareast-font-family:"Times New Roman";font-weight:
normal'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_31c1356f-9044-4919-b1c9-556d7d74575e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-fareast-font-family:"Times New Roman";font-weight:
normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.<!--[if supportFields]><span style='font-size:11.0pt;
mso-fareast-font-family:"Times New Roman";font-weight:normal'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1a8a21d9-df1e-49e4-b112-5e652fe3df35 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-fareast-font-family:"Times New Roman";font-weight:
normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p><em>Hypersensitivity</em><!--[if supportFields]><i><span
style='font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f7dd24d4-a025-4a75-9aa1-ec4e37bfd884 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span></i><![endif]--></p><p>Hypersensitivity reactions, including urticaria and angioedema, have been reported with use of EBGLYSS. If a serious hypersensitivity reaction occurs, discontinue EBGLYSS and institute appropriate therapy.</p><p><em>Conjunctivitis and Keratitis</em><!--[if supportFields]><i><span style='font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0789991c-73ee-4df5-90ad-98c218fd56d0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span></i><![endif]--></p><p>Conjunctivitis and keratitis adverse reactions have been reported in clinical trials.</p><p>Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received EBGLYSS compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered during the treatment period <em>[see Undesirable effects (4.8)]</em>.</p><p>Advise patients to report new onset or worsening eye symptoms to their healthcare provider.</p><p><em>Parasitic (Helminth) Infections</em><!--[if supportFields]><i><span style='font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b5cd96e0-2b84-44fd-8b40-ce454bc7733d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span></i><![endif]--></p><p>Patients with known helminth infections were excluded from participation in clinical studies. It is unknown if EBGLYSS will influence the immune response against helminth infections by inhibiting IL-13 signaling.</p><p>Treat patients with pre-existing helminth infections before initiating treatment with EBGLYSS. If patients become infected while receiving EBGLYSS and do not respond to antihelminth treatment, discontinue treatment with EBGLYSS until the infection resolves.</p><p><em>Risk of Infection with Live Vaccines</em><!--[if supportFields]><i><span
style='font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_80f69708-ab29-4807-b51b-b027d0f47462 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span></i><![endif]--></p><p>EBGLYSS may alter a patient&rsquo;s immunity and increase the risk of infection following administration of live vaccines. Prior to initiating therapy with EBGLYSS, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid use of live vaccines in patients treated with EBGLYSS. No data are available on the response to live or non-live vaccines.</p><p><u>Vaccinations</u><!--[if supportFields]><u><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ea602864-b936-41b1-959d-ba66b8329769 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>Prior to initiating therapy with lebrikizumab, it is recommended that patients are brought up to date with all age-appropriate immunisations according to current immunisation guidelines. Live and live attenuated vaccines should not be given concurrently with lebrikizumab as clinical safety and efficacy has not been established. Immune responses to non-live vaccines were assessed in a combined tetanus, diphtheria and acellular pertussis vaccine (TdaP) and a meningococcal polysaccharide vaccine (see section 4.5).<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-ansi-language:EN-US'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_739f9c35-32b8-4c30-9169-d64a283d792c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-ansi-language:EN-US'><span
style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p><u>Live vaccines </u></p><p>The safety and efficacy of concurrent use of lebrikizumab with live and live attenuated vaccines has not been studied. Live and live attenuated vaccines should not be given concurrently with lebrikizumab.</p><p><u>Non-live vaccines </u></p><p>Immune responses to non-live vaccines were assessed in a study in which adult patients with atopic dermatitis were treated with lebrikizumab 500 mg at weeks 0 and 2 followed by lebrikizumab 250 mg every other week. After 12 weeks of lebrikizumab administration, patients were vaccinated with a combined tetanus, diphtheria, and acellular pertussis vaccine TdaP vaccine (T cell-dependent) and a meningococcal polysaccharide vaccine (T cell-independent) and immune responses were assessed 4 weeks later. Antibody responses to both non-live vaccines were not negatively impacted by the concomitant lebrikizumab treatment. No adverse interactions between the non-live vaccines and lebrikizumab were noted in the study. Therefore, patients receiving lebrikizumab may receive concurrent inactivated or non-live vaccinations. For information on live vaccines see section 4.4.</p><p><u>Concomitant therapies </u></p><p>Given that lebrikizumab is a monoclonal antibody, no pharmacokinetic interactions are expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><!--[if supportFields]><u><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_221ae3d0-e015-45c3-b7fc-bc2f06f9b14d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>There are limited amount of data from the use of lebrikizumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of lebrikizumab during pregnancy.<!--[if supportFields]><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8f5a0149-7a91-47e2-8e7a-629f1e5010c3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p><u>Breast-feeding</u><!--[if supportFields]><u><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ced8d4a0-c6a9-484b-97da-633cd8f1b4a9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>It is unknown whether lebrikizumab is excreted in human milk or absorbed systemically after ingestion. Maternal IgG is known to be present in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue from lebrikizumab therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.<!--[if supportFields]><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_97a61a12-0d4e-40e7-bc07-3c5770586c94 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p><u>Fertility</u><!--[if supportFields]><u><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_5cc67247-211e-4406-9201-c2dec69d1a02 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-end'></span></span></u><![endif]--></p><p>Animal studies showed no impairment of fertility (see section 5.3).<!--[if supportFields]><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_1217b171-1932-472c-9047-69389f69cc2b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known effects on the ability to drive or use machines associated with the use of lebrikizumab.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most common adverse reactions are conjunctivitis (6.9%), injection site reactions (2.6%), conjunctivitis allergic (1.8%) and dry eye (1.4%).</p><p><u>Tabulated list of adverse reactions</u></p><p>Across all clinical studies in atopic dermatitis, a total of 1720 patients were administered lebrikizumab, of which, 891 patients were exposed to lebrikizumab for at least one year. Unless otherwise stated, the frequencies are based on a pool of 4 randomised, double-blind studies in patients with moderate-to-severe atopic dermatitis where 783 patients were treated with subcutaneous lebrikizumab during the placebo-controlled period (first 16 weeks of treatment).</p><p>Listed in <!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;font-family:"Arial",sans-serif'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>REF _Ref87623995 \h<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 1<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000D0000005F00520065006600380037003600320033003900390035000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-end'></span></span><![endif]--> are adverse reactions observed from clinical trials presented by system organ class and frequency, using the following categories: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1 000 to &lt; 1/100); rare (&ge; 1/10 000 to &lt; 1/1 000); very rare (&lt; 1/10 000).</p><p>Table <!--[if supportFields]><span style='mso-bookmark:_Ref87623995'></span><span
style='mso-element:field-begin'></span><span style='mso-bookmark:_Ref87623995'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>SEQ Table \* ARABIC<span
style='mso-element:field-separator'></span></span></span><![endif]-->1<!--[if supportFields]><span
style='mso-bookmark:_Ref87623995'></span><span style='mso-element:field-end'></span><![endif]-->. List of adverse reactions</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Conjunctivitis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Herpes zoster</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Eosinophilia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Conjunctivitis allergic</p><p>Dry eye</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Keratitis</p><p>Blepharitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Injection site reaction</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em><u>Conjunctivitis and related events</u></em></p><p>During the first 16 weeks of treatment conjunctivitis, conjunctivitis allergic and keratitis were reported more frequently in patients treated with lebrikizumab (6.9%, 1.8% and 0.6% respectively) compared to placebo (1.8%, 0.7% and 0.3%).</p><p>During maintenance treatment period (16-52 weeks) the incidence of conjunctivitis and conjunctivitis allergic with lebrikizumab was 5.0% and 5.9% respectively.</p><p>Across all clinical studies<em>, among lebrikizumab-treated patients</em> treatment discontinuation due to conjunctivitis and conjunctivitis allergic occurred in 0.7% and 0.3% of cases, respectively. Severe cases of conjunctivitis and conjunctivitis allergic occurred in 0.1% and 0.2% of cases, respectively. 72% of patients recovered, of those 57% recovered within 90 days.</p><p><em><u>Eosinophilia</u></em></p><p>Adverse reactions of eosinophilia were reported in 0.6% of patients treated with lebrikizumab and 0.8% of patients treated with placebo during the initial treatment period. Lebrikizumab-treated patients had a greater mean increase from baseline in eosinophil count compared to patients treated with placebo. In general, the increase in the lebrikizumab-treated patients was mild or moderate and transient. Eosinophilia <u>&gt;</u>5000 cells/mcL was observed in 0.4% lebrikizumab-treated patients and none of the placebo-treated patients. Eosinophilia did not result in treatment discontinuation and no eosinophil-related disorders were reported.</p><p><em><u>Injection site reactions</u></em></p><p>Injection site reactions were reported more frequently in patients who received lebrikizumab (2.6%) compared to placebo (1.5%). The majority (95 %) of injection site reactions were mild or moderate in severity, and few patients (&lt;&nbsp;0.5%) discontinued lebrikizumab treatment.</p><p><em><u>Herpes zoster</u></em></p><p>Herpes zoster was reported in 0.6% of the patients<s> </s>treated with lebrikizumab and none of the patients in the placebo group. All herpes zoster events reported were mild or moderate in severity and none led to permanent discontinuation of treatment.</p><p><em><u>Long term safety</u></em></p><p>The long-term safety of lebrikizumab was assessed in 5 clinical studies. In the two monotherapy studies (ADvocate-&nbsp;1, ADvocate-2) up to 52 weeks and in patients enrolled in the TCS combination therapy study (ADhere) and followed in a long-term extension study (ADjoin) for a total of 56 weeks and the monotherapy ADore study in adolescents for also up to 52 weeks. The safety profile of lebrikizumab as monotherapy through week 52 or in combination with TCS through week 56 is consistent with the safety profile observed up to week 16.</p><p><u>Paediatric population</u></p><p><em><u>Adolescents 12 to 17 years of age</u></em></p><p>The safety of lebrikizumab was assessed in 372 patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, including 270 patients exposed for at least one year. The safety profile of lebrikizumab in these patients was similar to the safety profile in adults with atopic dermatitis.</p><p>Pediatric Use<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_4e54357a-c886-4437-b2e1-4df2b85bc708 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>The safety and effectiveness of EBGLYSS have been established in pediatric subjects aged 12 to less than 18 years who weigh at least 40 kg with moderate-to-severe atopic dermatitis. A total of 372 pediatric subjects were exposed to EBGLYSS with 270 subjects exposed to EBGLYSS for at least one year. The safety and effectiveness of EBGLYSS in pediatric subjects aged 12 years to less than 18 years who weigh less than 40 kg and pediatric subjects less than 12&nbsp;years of age with moderate to severe atopic dermatitis have not been established.</p><p>Geriatric Use<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_717103be-07ed-4384-bb92-e063f37f13eb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Of the 1348 adult subjects with moderate-to-severe atopic dermatitis exposed to EBGLYSS, a total of 123 were 65&nbsp;years or older, and 29 subjects were 75 years or older. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects <em>[see</em><em> Pharmacokinetic properties (5.2</em><em>)</em><em>]</em>.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed here.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><u>Please report adverse drug events to: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa &nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single intravenous doses up to 10&nbsp;mg/kg and multiple subcutaneous doses up to 500&nbsp;mg have been administered to humans in clinical trials without dose-limiting toxicity. In the event of overdosage, monitor the patient for any signs or symptoms of adverse reactions and institute appropriate symptomatic treatment immediately. There is no known antidote to lebrikizumab overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: {agents for dermatitis, excluding corticosteroids}, ATC code: D11AH10</p><p><u>Mechanism of action</u></p><p>Lebrikizumab is an immunoglubulin (IgG4) monoclonal antibody that binds with high affinity (&lt;10&nbsp;pM) to interleukin (IL)‑13 and selectively inhibits IL‑13 signalling through the IL‑4 receptor alpha (IL‑4R&alpha;)/ IL-13 receptor alpha 1 (IL‑13R&alpha;1) heterodimer, thereby inhibiting the downstream effects of IL‑13. Inhibition of IL-13 signalling is expected to be of benefit in diseases in which IL-13 is a key contributor to the disease pathogenesis. Lebrikizumab does not prevent the binding of IL-13 to the IL-13 receptor alpha 2 (IL-13R&alpha;2 or decoy receptor), which allows the internalisation of IL-13 into the cell.</p><p><u>Pharmacodynamic effects</u></p><p>In lebrikizumab clinical studies, lebrikizumab reduced the levels of serum periostin, total immunoglobulin E (IgE), CC chemokine ligand (CCL)17 [thymus and activation-regulated chemokine (TARC)], CCL18 [pulmonary and activation-regulated chemokine (PARC)], and CCL13 [monocyte chemotactic protein-4 (MCP-4)]. The decreases in the type 2 inflammation mediators provide indirect evidence of inhibition of the IL-13 pathway by lebrikizumab.</p><p><u>Clinical efficacy and safety</u></p><p><em><u>Adults and adolescents with atopic dermatitis</u></em></p><p>The efficacy and safety of lebrikizumab as monotherapy (ADvocate-1, ADvocate-2) and with concomitant TCS (ADhere) were evaluated in three randomised, double-blind, placebo-controlled pivotal studies in 1062 adults and adolescents (aged 12 to 17 years and weighing &ge;40&nbsp;kg) with moderate-to-severe atopic dermatitis, defined by an Eczema Area and Severity Index (EASI) &ge;&nbsp;16, Investigator&rsquo;s Global Assessment (IGA) &ge;&nbsp;3, and a body surface area (BSA) involvement of &ge;&nbsp;10%. Patients enrolled into the three studies previously had an inadequate response to topical medication or determination that topical treatments are otherwise medically inadvisable.</p><p>In all three studies, patients received an initial dose of 500&nbsp;mg of lebrikizumab (two 250&nbsp;mg injections) at weeks 0 and 2, followed by 250&nbsp;mg every other week (Q2W) until week 16, or matching placebo in a 2:1 ratio. In ADhere, study patients also received concomitant low-to-mid potency TCS or TCI on active lesions. Patients were permitted to receive rescue treatment at the discretion of the investigator to control intolerable symptoms of atopic dermatitis. Patients requiring systemic rescue treatment were discontinued from study treatment.</p><p>Patients responding to treatment at week 16 in ADvocate-1 and 2 studies (i.e., achieved IGA 0 or 1, or at least a 75% reduction in EASI (EASI 75) without having received any rescue therapy) were re-randomised in a blinded manner to (i) lebrikizumab 250&nbsp;mg Q2W; (ii) lebrikizumab 250&nbsp;mg <u>every 4 weeks</u> (Q4W); or (iii) matching placebo up to 52 weeks.</p><p>In ADvocate-1 and 2, patients not achieving IGA 0 or 1 or EASI 75 at week 16, or who received rescue medication prior to week 16, were entered into an Escape Arm and treated with open-label lebrikizumab 250 mg Q2W through Week 52.</p><p>In ADvocate-1 and ADvocate-2, after completing the 52-week study, and in ADhere, after completing the 16-week study, patients were offered the option to continue treatment in a separate long-term extension study (ADjoin).</p><p><em><u>Endpoints</u></em></p><p>In all three studies, the co-primary endpoints were the percentage of patients with IGA 0 or 1 (&ldquo;clear&rdquo; or &ldquo;almost clear&rdquo;), with a &ge;2-point reduction from baseline, and the percentage of patients achieving EASI 75 from baseline to week 16. Key secondary endpoints (adjusted for multiplicity) included the percentage of patients who achieved at least a 90% reduction in EASI (EASI 90), percentage of patients with at least 4-point improvement from baseline in Pruritus Numerical Rating Scale (Pruritus NRS), percentage of patients with at least 4-point improvement from baseline in Dermatology Life Quality Index (DLQI)&nbsp; and interference of itch on sleep (Sleep-Loss Scale) patient-reported, single-item, daily scale measuring the extent of interference of itch on sleep over the last night on a 5-point Likert scale. An additional secondary endpoint (not adjusted for multiplicity) included the change from baseline in Patient Oriented Eczema Measure (POEM).</p><p><em><u>Subjects</u></em></p><p><em>Baseline characteristics</em></p><p>The monotherapy studies ADvocate-1 and ADvocate-2 enrolled 424 and 427, respectively, and across studies the mean age was 35.8, the mean weight was 77.1 kg, 49.9% were female, 63.7% were white, 22.6% were Asian, and 9.9% were black; 12.0% were adolescents (12 to 17 years). Overall, 61.5% of patients had a baseline IGA of 3 (moderate <u>atopic dermatitis</u>), 38.5% of patients had a baseline IGA of 4 (severe <u>atopic dermatitis</u>), and 54.8% of patients had received prior systemic treatment. The mean baseline EASI was 29.6, the mean baseline Pruritus NRS was 7.2 and the mean baseline DLQI was 15.5.</p><p>The concomitant TCS study ADhere enrolled 211 patients and the mean age was 37.2, the mean weight was 76.2 kg, 48.8% were female, 61.6% were white, 14.7% were Asian, and 13.3% were black; 21.8% were adolescents. In this study, 69.2% of patients had a baseline IGA of 3 (moderate <u>atopic dermatitis</u>), 30.8% of patients had a baseline IGA of 4 (severe <u>atopic dermatitis</u>), and 47.4% of patients had received prior systemic treatment. The mean baseline EASI was 27.3, the mean baseline Pruritus NRS was 7.1 and the mean baseline DLQI was 14.4.</p><p><em><u>Clinical response</u></em></p><p><em>Monotherapy studies (ADvocate-1 and ADvocate-2) &ndash; induction period, weeks 0-16</em></p><p>In ADvocate-1 and ADvocate-2, a significantly greater proportion of patients randomised to lebrikizumab 250 mg Q2W achieved IGA 0 or 1 with a &ge;2-point improvement from baseline, EASI 75, EASI 90, and an improvement of &ge;4 points in Pruritus NRS and DLQI compared to placebo at week 16 (see <!--[if supportFields]><span
lang=EN-GB style='font-family:"Arial",sans-serif'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'> </span>REF _Ref132621901
\h<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->Table 3<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003100330032003600320031003900300031000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-family:"Arial",sans-serif'><span style='mso-element:field-end'></span></span><![endif]-->).</p><p>In both monotherapy studies, lebrikizumab reduced daily worst itch severity compared to placebo, as measured by the percent change from baseline in Pruritus NRS, already since week 1 of treatment. The improvement in Pruritus NRS occurred in conjunction with improvements in skin inflammation related to atopic dermatitis and quality of life.</p><p>Clinical Response at Week 16 (ADvocate 1, ADvocate 2, and ADhere)</p><p>The results of the EBGLYSS monotherapy trials (ADvocate 1 and ADvocate 2) and the EBGLYSS + TCS trial (ADhere) are presented in Table 2.</p><p>Table 2: Efficacy Results of EBGLYSS With or Without Concomitant TCS at Week 16<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:644px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>ADvocate 1</p></td><td colspan="2" style="vertical-align:top"><p>ADvocate 2</p></td><td colspan="2" style="vertical-align:top"><p>ADhere</p></td></tr><tr><td style="vertical-align:top"><p>EBGLYSS 250&nbsp;mg</p><p>Q2W<sup>b</sup></p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>EBGLYSS 250 mg</p><p>Q2W<sup>b</sup></p></td><td style="vertical-align:top"><p>Placebo</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>EBGLYSS 250 mg<sup>b</sup></p><p>Q2W + TCS</p></td><td style="vertical-align:top"><p>Placebo + TCS</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of subjects</strong></p></td><td style="vertical-align:top"><p>283</p></td><td style="vertical-align:top"><p>141</p></td><td style="vertical-align:top"><p>281</p></td><td style="vertical-align:top"><p>146</p></td><td style="vertical-align:top"><p>145</p></td><td style="vertical-align:top"><p>66</p></td></tr><tr><td style="vertical-align:top"><p>IGA 0 or 1<sup>c</sup></p></td><td style="vertical-align:top"><p>43%</p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>33%</p></td><td style="vertical-align:top"><p>11%</p></td><td style="vertical-align:top"><p>41%</p></td><td style="vertical-align:top"><p>22%</p></td></tr><tr><td style="vertical-align:top"><p>EASI-75</p></td><td style="vertical-align:top"><p>59%</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>52%</p></td><td style="vertical-align:top"><p>18%</p></td><td style="vertical-align:top"><p>70%</p></td><td style="vertical-align:top"><p>42%</p></td></tr><tr><td style="vertical-align:top"><p>EASI-90</p></td><td style="vertical-align:top"><p>38%</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>31%</p></td><td style="vertical-align:top"><p>10%</p></td><td style="vertical-align:top"><p>41%</p></td><td style="vertical-align:top"><p>22%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of subjects with baseline Pruritus NRS score &ge;4</strong></p></td><td style="vertical-align:top"><p>263</p></td><td style="vertical-align:top"><p>130</p></td><td style="vertical-align:top"><p>253</p></td><td style="vertical-align:top"><p>134</p></td><td style="vertical-align:top"><p>130</p></td><td style="vertical-align:top"><p>57</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus NRS &ge;4 point improvement</p></td><td style="vertical-align:top"><p>46%</p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>40%</p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>51%</p></td><td style="vertical-align:top"><p>32%</p></td></tr></tbody></table><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Subjects who received rescue therapy or discontinued treatment due to lack of efficacy were analyzed as non-responders. Data after treatment discontinuation due to any other reason were considered missing. Any missing data was imputed using MCMC-MI.</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp; </sup>Subjects received 500&nbsp;mg of EBGLYSS at Week 0 and Week 2, and 250&nbsp;mg Q2W up to Week&nbsp;16</p><p><sup>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Primary endpoint. Responder was defined as a subject with an IGA 0 or 1 (&ldquo;clear&rdquo; or &ldquo;almost clear&rdquo;) and a reduction of &ge;2&nbsp;points on a 0-4 IGA scale</p><p>In the two studies, fewer patients randomised to lebrikizumab needed rescue treatment (topical corticosteroids, systemic corticosteroids, immunosuppressants) as compared to patients randomised to placebo (14.7% versus 36.6%, respectively, across both studies).</p><p><!--[if supportFields]><span lang=EN-GB style='font-family:
"Arial",sans-serif'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>REF _Ref133229078 \h <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Figure 1<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003100330033003200320039003000370038000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-family:"Arial",sans-serif'><span style='mso-element:field-end'></span></span><![endif]--> and <!--[if supportFields]><span
lang=EN-GB style='font-family:"Arial",sans-serif'><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'> </span>REF _Ref133229087 \h
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]-->Figure 2<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003100330033003200320039003000380037000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-family:"Arial",sans-serif'><span style='mso-element:field-end'></span></span><![endif]--> show the mean percent change from baseline in EASI and Pruritus NRS up to week 16.</p><table border="0" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p>Figure <!--[if supportFields]><span
  style='mso-bookmark:_Ref133229078'></span><span style='mso-element:field-begin'></span><span
  style='mso-bookmark:_Ref133229078'><span lang=EN-GB style='font-family:"Arial",sans-serif;
  mso-fareast-language:EN-GB'><span style='mso-spacerun:yes'> </span>SEQ Figure
  \* ARABIC <span style='mso-element:field-separator'></span></span></span><![endif]-->1<!--[if supportFields]><span
  style='mso-bookmark:_Ref133229078'></span><span style='mso-element:field-end'></span><![endif]-->. Mean EASI percent change from baseline to week 16 in ADvocate 1 and 2<!--[if supportFields]><span
  lang=EN-GB style='font-family:"Arial",sans-serif;mso-fareast-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_c40d9f51-2d80-4c94-b48a-cab8ea4db2b3 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-family:"Arial",sans-serif;mso-fareast-language:EN-GB'><span
  style='mso-element:field-end'></span></span><![endif]--></p><p><img alt="" width="472" height="426" src="data:image/png;base64,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" /></p></td><td style="vertical-align:top"><p>Figure <!--[if supportFields]><span
  style='mso-bookmark:_Ref133229087'></span><span style='mso-element:field-begin'></span><span
  style='mso-bookmark:_Ref133229087'><span lang=EN-GB style='font-family:"Arial",sans-serif;
  mso-fareast-language:EN-GB'><span style='mso-spacerun:yes'> </span>SEQ Figure
  \* ARABIC <span style='mso-element:field-separator'></span></span></span><![endif]-->2<!--[if supportFields]><span
  style='mso-bookmark:_Ref133229087'></span><span style='mso-element:field-end'></span><![endif]-->. Mean pruritus NRS percent change from baseline to week 16 in ADvocate 1 and 2<!--[if supportFields]><span
  lang=EN-GB style='font-family:"Arial",sans-serif;mso-fareast-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_9fd5c004-a601-42f9-a8a5-ba1651110602 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-family:"Arial",sans-serif;mso-fareast-language:EN-GB'><span
  style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><img alt="" width="471" height="426" src="data:image/png;base64,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" /></p></td></tr></tbody></table><p>***p&lt;0.001 versus placebo</p><p>&nbsp;</p><p>Treatment effects in subgroups (weight, age, gender, race, severity, and prior use of systemic treatments) in ADvocate-1 and ADvocate-2 were consistent with the results in the overall study population during the induction phase.</p><p><em>Monotherapy Studies (ADvocate-1 and ADvocate-2) &ndash; maintenance period, weeks 16-52</em></p><p>To evaluate maintenance of response, 157 subjects from ADvocate-1 and 134 subjects from ADvocate-2 treated with lebrikizumab 250&nbsp;mg Q2W, who achieved IGA 0 or 1 or EASI&nbsp;75 at week 16 without topical or systemic rescue treatment, were re-randomised in a blinded manner 2:2:1 to an additional 36-week treatment of (i) lebrikizumab 250&nbsp;mg Q2W, or (ii) lebrikizumab 250&nbsp;mg Q4W, or (iii) matching placebo for a cumulative 52-week study treatment (see <!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>REF _Ref132622029 \h <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 4<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003100330032003600320032003000320039000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif'><span
style='mso-element:field-end'></span></span><![endif]-->).</p><p>Maintenance and Durability of Response (Week 16 to Week 52)</p><p>Monotherapy Trials</p><p>The results of EBGLYSS-treated subjects achieving IGA 0 or 1 or EASI-75, and did not receive rescue therapy at Week&nbsp;16 who were re-randomized to 36 weeks of maintenance treatment with EBGLYSS 250&nbsp;mg Q2W, EBGLYSS 250&nbsp;mg Q4W, or placebo in ADvocate 1 and Advocate 2 are presented in Table 3.</p><p>&nbsp;</p><p>Table 3: Efficacy Results of EBGLYSS at Week 52 in ADvocate 1 and ADvocate 2<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:688px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>ADvocate 1</p></td><td colspan="3" style="vertical-align:top"><p>ADvocate 2</p></td></tr><tr><td style="vertical-align:top"><p>EBGLYSS 250&nbsp;mg</p><p>Q2W</p></td><td style="vertical-align:top"><p>EBGLYSS 250 mg Q4W</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>EBGLYSS 250&nbsp;mg</p><p>Q2W</p></td><td style="vertical-align:top"><p>EBGLYSS 250 mg</p><p>Q4W</p></td><td style="vertical-align:top"><p>Placebo</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of subjects who were IGA of 0 or 1 Responders at Week&nbsp;16<sup>b</sup></strong></p></td><td><p>&nbsp;</p><p>45</p></td><td><p>&nbsp;</p><p>45</p></td><td><p>&nbsp;</p><p>22</p></td><td><p>&nbsp;</p><p>32</p></td><td><p>&nbsp;</p><p>32</p></td><td><p>&nbsp;</p><p>16</p></td></tr><tr><td style="vertical-align:top"><p>IGA of 0 or 1<sup>b</sup> at Week 52</p></td><td><p>76%</p></td><td><p>74%</p></td><td><p>47%</p></td><td><p>65%</p></td><td><p>81%</p></td><td><p>50%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of subjects who were EASI-75 Responders at Week&nbsp;16</strong></p></td><td><p>61</p></td><td><p>62</p></td><td><p>30</p></td><td><p>51</p></td><td><p>53</p></td><td><p>27</p></td></tr><tr><td style="vertical-align:top"><p>EASI-75 at Week&nbsp;52</p></td><td><p>79%</p></td><td><p>79%</p></td><td><p>61%</p></td><td><p>77%</p></td><td><p>85%</p></td><td><p>72%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of subjects with baseline Pruritus NRS score &ge;4 and reported Pruritus NRS &ge;4 point improvement at Week&nbsp;16</strong></p></td><td><p>38</p></td><td><p>29</p></td><td><p>17</p></td><td><p>23</p></td><td><p>36</p></td><td><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus NRS &ge;4 point improvement at Week&nbsp;52</p></td><td><p>81%</p></td><td><p>80%</p></td><td><p>65%</p></td><td><p>90%</p></td><td><p>88%</p></td><td><p>68%</p></td></tr></tbody></table><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Subjects who received systemic rescue therapy, discontinued treatment due to lack of efficacy were analyzed as non-responders. Data after topical rescue medication or treatment discontinuation due to any other reason were considered missing. Any missing data were imputed using MCMC-MI.</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp; </sup>Responder was defined as a subject with an IGA 0 or 1 (&ldquo;clear&rdquo; or &ldquo;almost clear&rdquo;) and a reduction of &ge;2 points on a 0-4 IGA scale</p><p>&nbsp;</p><p>Among subjects who received lebrikizumab during the induction period and continued lebrikizumab 250 mg Q2W open-label treatment up to week 52 in the Escape Arm, 58% achieved EASI 75 and 28% achieved IGA 0 or 1 with a &ge;2-point improvement from baseline at week 52 in ADvocate-1 and ADvocate-2 (pooled).</p><p><em>Concomitant TCS Study (ADhere)</em></p><p>In ADhere, from baseline to week 16, a significantly greater proportion of patients randomised to and dosed with lebrikizumab 250&nbsp;mg Q2W + TCS achieved IGA 0 or 1, EASI 75, and improvements of &ge;&nbsp;4 points in the Pruritus NRS and DLQI compared to placebo + TCS (see Table 6).</p><p>Table <!--[if supportFields]><span style='mso-bookmark:_Ref105517158'><span
style='mso-bookmark:_Ref92963020'></span></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref105517158'><span style='mso-bookmark:_Ref92963020'><span
lang=EN-GB style='font-family:"Arial",sans-serif'>SEQ Table \* ARABIC<span
style='mso-element:field-separator'></span></span></span></span><![endif]-->4<!--[if supportFields]><span
style='mso-bookmark:_Ref105517158'><span style='mso-bookmark:_Ref92963020'></span></span><span
style='mso-element:field-end'></span><![endif]-->. Efficacy results of lebrikizumab combination therapy with TCS at week 16 in ADhere</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ADhere </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 16</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo + TCS</strong></p><p>&nbsp;</p><p><strong>N=66</strong></p></td><td style="vertical-align:top"><p><strong>LEB<br />250&nbsp;mg Q2W + TCS</strong></p><p><strong>N=145</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>IGA 0 or 1, %<sup>a</sup></strong></p></td><td><p>22.1</p></td><td><p>41.2*</p></td></tr><tr><td style="vertical-align:top"><p><strong>EASI 75, %<sup>b</sup></strong></p></td><td><p>42.2</p></td><td><p>69.5***</p></td></tr><tr><td style="vertical-align:top"><p><strong>EASI 90, %<sup>b</sup></strong></p></td><td><p>21.7</p></td><td><p>41.2**</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pruritus NRS (&ge;&nbsp;4-point improvement), %<sup>c</sup></strong></p></td><td><p>31.9</p></td><td><p>50.6*</p></td></tr><tr><td style="vertical-align:top"><p><strong>DLQI (Adults) (&ge; 4-point improvement), %<sup>d</sup></strong></p></td><td><p>58.7</p></td><td><p>77.4*</p></td></tr></tbody></table><p><sup>a</sup> Subjects with IGA 0 or 1 (&ldquo;clear&rdquo; or &ldquo;almost clear&rdquo;) with a reduction of &ge;&nbsp;2 points from baseline on a 0-4 IGA scale.</p><p><sup>b </sup>Subjects with a 75% or 90% reduction in EASI from Baseline to week 16, respectively.</p><p><sup>c</sup> The percentage is calculated relative to the number of subjects with a baseline Pruritus NRS &ge; 4.</p><p><sup>d</sup> The percentage is calculated relative to the number of subjects with a baseline DLQI &ge;4.</p><p><sup>*</sup> p&lt;0.05;<sup> </sup>**p&lt;0.01; ***<sup> </sup>p&lt;0.001 versus placebo versus placebo.</p><p>&nbsp;</p><p>In ADhere, subjects who received lebrikizumab 250 mg Q2W+TCS from week 0 to 16 used high potency TCS as rescue medication less often as compared to subjects who received placebo + TCS (1.4% and 4.5%, respectively).</p><p>In the concomitant TCS study (ADhere) lebrikizumab 250 mg Q2W significantly improved the EASI and Pruritus NRS mean percent change from baseline to week 16 <u>(76.76% and 50.7%) </u>compared to TCS + placebo (53.12% and 35.5%).</p><p>Treatment effects in subgroups (weight, age, gender, race, severity or prior use of systemic treatment) in ADhere were consistent with the results in the overall study population.</p><p>Subjects who responded at week 16 in ADhere and entered ADjoin were treated with lebrikizumab 250&nbsp;mg Q4W maintained their responses up to 56 weeks (86.8% for IGA 0 or 1 and 81.2% for EASI&nbsp;75).</p><p><em><u>Patient-reported outcomes and health-related quality of life</u></em></p><p>In both monotherapy studies (ADvocate-1 and ADvocate-2) and in the concomitant TCS study (ADhere) lebrikizumab 250&nbsp;mg Q2W significantly improved POEM and interference of itch on sleep (Sleep-Loss Scale) at week 16 compared to placebo.</p><p>The efficacy of lebrikizumab 250 mg Q2W, both as monotherapy and in combination with TCS, compared with placebo was evaluated across 3 pivotal Phase 3 studies. In the first 16 weeks of&nbsp;all 3 studies, participants who were given lebrikizumab 250 mg Q2W demonstrated statistically significant and clinically meaningful improvement across multiple investigator-assessed clinical outcomes (IGA 0 or 1, EASI 75, and EASI 90) and PROs related to itch (Pruritus NRS), interference of itch on sleep, QoL (DLQI), and disease severity (POEM).</p><p><strong>Table 5: Proportion of Participants with a 4-Point or Greater Improvement in DLQI and DLQI Mean Change from Baseline at Week 16 Primary Estimand (Hybrid) with MCMC-MI</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Study KGAB</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study KGAC</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study KGAD</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>PBO</strong></p></td><td style="vertical-align:top"><p><strong>LEB</strong></p><p><strong>250mg</strong></p><p><strong>Q2W</strong></p></td><td style="vertical-align:top"><p><strong>PBO</strong></p></td><td style="vertical-align:top"><p><strong>LEB</strong></p><p><strong>250mg</strong></p><p><strong>Q2W</strong></p></td><td style="vertical-align:top"><p><strong>PBO +</strong></p><p><strong>TCS</strong></p></td><td style="vertical-align:top"><p><strong>LEB 250mg Q2W</strong></p><p><strong>+ TCS</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Percentage of participants with 4-point or greater improvement</strong></p></td></tr><tr><td style="vertical-align:top"><p>Participants with</p><p>DLQI &ge;4 at BL<sup>a</sup>,</p><p>N</p></td><td style="vertical-align:top"><p>116</p></td><td style="vertical-align:top"><p>226</p></td><td style="vertical-align:top"><p>115</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>215</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>105</p></td></tr><tr><td style="vertical-align:top"><p>Response, n</p><p>(%)</p></td><td style="vertical-align:top"><p>39</p><p>(33.8)</p></td><td style="vertical-align:top"><p>171</p><p>(75.6)</p></td><td style="vertical-align:top"><p>39</p><p>(33.6)</p></td><td style="vertical-align:top"><p>143</p><p>(66.3)</p></td><td style="vertical-align:top"><p>28</p><p>(58.7)</p></td><td style="vertical-align:top"><p>81</p><p>(77.4)</p></td></tr><tr><td style="vertical-align:top"><p>Diff vs. PBO, %</p><p>(95% CI)<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>41.8</p><p>(31.2, 52.3)</p></td><td colspan="2" style="vertical-align:top"><p>33.0</p><p>(22.2, 43.8)</p></td><td colspan="2" style="vertical-align:top"><p>17.2</p><p>(0.1, 34.3)</p></td></tr><tr><td style="vertical-align:top"><p>p-value vs. PBO<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;.001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;.001</p></td><td colspan="2" style="vertical-align:top"><p>.036</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Mean change from Baseline in DLQI</strong></p></td></tr><tr><td style="vertical-align:top"><p>N<sup>c</sup></p></td><td style="vertical-align:top"><p>121</p></td><td style="vertical-align:top"><p>239</p></td><td style="vertical-align:top"><p>118</p></td><td style="vertical-align:top"><p>218</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>109</p></td></tr><tr><td style="vertical-align:top"><p>Baseline DLQI</p><p>(SD)</p></td><td style="vertical-align:top"><p>15.7</p><p>(7.2)</p></td><td style="vertical-align:top"><p>15.3</p><p>(7.4)</p></td><td style="vertical-align:top"><p>15.9</p><p>(7.6)</p></td><td style="vertical-align:top"><p>15.4</p><p>(7.0)</p></td><td style="vertical-align:top"><p>13.5</p><p>(7.5)</p></td><td style="vertical-align:top"><p>14.9</p><p>(7.2)</p></td></tr><tr><td style="vertical-align:top"><p>LSM change (SE)</p></td><td style="vertical-align:top"><p>-2.9</p><p>(1.1)</p></td><td style="vertical-align:top"><p>-8.7</p><p>(1.1)</p></td><td style="vertical-align:top"><p>-2.4</p><p>(1.2)</p></td><td style="vertical-align:top"><p>-7.3</p><p>(1.2)</p></td><td style="vertical-align:top"><p>-6.5</p><p>(1.9)</p></td><td style="vertical-align:top"><p>-9.8 (1.8)</p></td></tr><tr><td style="vertical-align:top"><p>LSM Diff vs. PBO</p><p>(SE)<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>-5.8</p><p>(0.68)</p></td><td colspan="2" style="vertical-align:top"><p>-4.9</p><p>(0.71)</p></td><td colspan="2" style="vertical-align:top"><p>-3.3</p><p>(1.0)</p></td></tr><tr><td style="vertical-align:top"><p>p-value vs. PBO<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;.001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;.001</p></td><td colspan="2" style="vertical-align:top"><p>.001</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Abbreviations: ANCOVA = analysis of covariance; BL = baseline; CI = confidence interval; CSR = clinical study report; Diff = difference; DLQI = Dermatology Life Quality Index; IGA = Investigator&rsquo;s Global Assessment; LEB = lebrikizumab; LSM = least standard mean; MCMC-MI = Markov Chain Monte Carlo multiple imputation; N = number of participants in the analysis population; n = number of participants in the specified category; PBO = placebo; Q2W = every 2 weeks; SD = standard deviation; SE = standard error; TCS = topical corticosteroids.</p><p><sup>a</sup> DLQI 4-point improvement response was analyzed in participants with a Baseline DLQI score of 4 or more.</p><p><sup>b</sup> Cochran-Mantel-Haenszel test adjusted by geographic region (US versus EU versus rest of world), age</p><p>(adolescent versus adult), and disease severity (IGA 3 versus 4).</p><p><sup>c</sup> Change from Baseline in DLQI analyzed in participants with nonmissing DLQI baseline values.</p><p><sup>d </sup>The ANCOVA model includes treatment, geographic region (US versus EU versus rest of the world), age group (adolescent participants 12 to &lt;18 versus adults &ge;18 years) and baseline IGA score (3,4) as fixed factors and baseline value as covariate.</p><p><em><u>Immunogenicity</u></em></p><p>Anti-drug antibodies (ADA) were commonly detected. No evidence of ADA impact on pharmacokinetics, efficacy or safety was observed.</p><p><em><u>Adolescents (12 to 17 years of age)</u></em></p><p>In the monotherapy studies ADvocate 1 and ADvocate 2, the mean age of adolescent patients was 14.6&nbsp;years, the mean weight was 68.2 kg, and 56.9% were female. In these studies, 63.7% had a baseline IGA of 3 (moderate <u>atopic dermatitis</u>), 36.3% had a baseline IGA of 4 (severe <u>atopic dermatitis</u>), and 47.1% had received prior systemic treatment. In the concomitant combination study with TCS ADhere, the mean age of adolescent patients was 14.6 years, mean weight was 62.2 kg, and 50.0% were female. In this study, 76.1% had a baseline IGA of 3 (moderate <u>atopic dermatitis</u>), 23.9% had a baseline IGA of 4 (severe <u>atopic dermatitis</u>), and 23.9% had received prior systemic treatment.</p><p>The efficacy results at week 16 in adolescent patients are presented in <!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-bidi-font-weight:
bold;mso-bidi-font-style:italic'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>REF _Ref130546424 \h <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table 7<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003100330030003500340036003400320034000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-bidi-font-weight:
bold;mso-bidi-font-style:italic'><span style='mso-element:field-end'></span></span><![endif]-->.</p><p>Table 6. Efficacy results of lebrikizumab monotherapy in ADvocate-1, ADvocate‑2 and lebrikizumab combination therapy with TCS in ADhere at week 16 in adolescent patients<!--[if supportFields]><span
style='mso-bookmark:_Hlk132736592'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk132736592'><span lang=EN-GB style='font-family:"Arial",sans-serif'>
DOCVARIABLE vault_nd_3753263c-09e1-4f4f-bd1c-237f5e38e496 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Hlk132736592'></span><span style='mso-element:field-end'></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p><strong>ADvocate-1</strong></p></td><td colspan="2"><p><strong>ADvocate-2</strong></p></td><td colspan="2"><p><strong>ADhere</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6"><p><strong>Week 16</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=18</strong></p></td><td style="vertical-align:top"><p><strong>LEB</strong></p><p><strong>250</strong><strong> </strong><strong>mg Q2W</strong></p><p><strong>N=37</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=17</strong></p></td><td style="vertical-align:top"><p><strong>LEB</strong></p><p><strong>250</strong><strong> </strong><strong>mg Q2W</strong></p><p><strong>N=30</strong></p></td><td style="vertical-align:top"><p><strong>Placebo + TCS</strong></p><p><strong>N=14</strong></p></td><td style="vertical-align:top"><p><strong>LEB</strong></p><p><strong>250&nbsp;mg Q2W + TCS</strong></p><p><strong>N=32</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>IGA 0 or 1, %<sup>a</sup></strong></p></td><td><p>22.2</p></td><td><p>48.6</p></td><td><p>5.9</p></td><td><p>44.1**</p></td><td><p>28.6</p></td><td><p>57.3</p></td></tr><tr><td style="vertical-align:top"><p><strong>EASI 75, %<sup>a</sup></strong></p></td><td><p>22.2</p></td><td><p>62.2**</p></td><td><p>12.0</p></td><td><p>61.7**</p></td><td><p>57.1</p></td><td><p>88.0*</p></td></tr><tr><td style="vertical-align:top"><p><strong>EASI 90, %</strong><strong><sup>a</sup></strong></p></td><td><p>16.7</p></td><td><p>45.9*</p></td><td><p>6.1</p></td><td><p>34.3*</p></td><td><p>28.6</p></td><td><p>55.1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pruritus NRS (&ge;&nbsp;4-point improvement), %<sup>b</sup></strong></p></td><td><p>22.8</p></td><td><p>54.3*</p></td><td><p>0.3</p></td><td><p>42.1</p></td><td><p>13.8</p></td><td><p>45.8</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>a</sup> At Week 16, subjects with IGA 0 or 1 (&ldquo;clear&rdquo; or &ldquo;almost clear&rdquo;) with a reduction of &ge;&nbsp;2 points from baseline on a 0-4 IGA scale, or a 75% or 90% reduction in EASI from baseline to week 16, respectively.</p><p><sup>b</sup> The percentage is calculated relative to the number of subjects with a baseline Pruritus NRS &ge;4.</p><p>* p&lt;0.05;<sup> </sup>**p&lt;0.01 versus placebo.</p></td></tr></tbody></table><p>Adolescent patients treated with lebrikizumab and lebrikizumab + TCS achieved clinically meaningful improvements in disease severity and maintained response up to week 52. Additional data from the single-arm ADore study with lebrikizumab in 206 adolescents support the efficacy of lebrikizumab in adolescent patients up to 52 weeks of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetics<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d7fadcc0-11a8-4d97-ab3b-99f0803ddd70 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Following the 500&nbsp;mg loading doses at Week 0 and Week 2, steady-state serum concentrations were achieved with the first 250&nbsp;mg Q2W dose at Week&nbsp;4.</p><p>Based on a population pharmacokinetic (PK) analysis, the steady-state maximum concentration (C<sub>max,ss</sub>), the steady-state average concentration (C<sub>avg,ss</sub>), and the steady-state trough concentration (C<sub>trough,ss</sub>) following the 250&nbsp;mg Q2W subcutaneous dose in patients with atopic dermatitis (AD) were 108&nbsp;&micro;g/mL, 100&nbsp;&micro;g/mL, and 87&nbsp;&micro;g/mL, respectively. The C<sub>max,ss</sub>, the C<sub>avg,ss</sub>, and the C<sub>trough,ss</sub> following the 250&nbsp;mg Q4W subcutaneous dose in patients with AD were 63&nbsp;&micro;g/mL, 51&nbsp;&micro;g/mL, and 36&nbsp;&micro;g/mL, respectively.</p><p>A longitudinal exposure-response model describing the PK and EASI relationship predicted EASI 75 response rates of 80% and 73% for 250&nbsp;mg Q4W and Q8W, respectively, at Week 52 for subjects who initially received 250&nbsp;mg Q2W and achieved EASI response criteria at Week&nbsp;16.</p><p>Absorption</p><p>Following a single subcutaneous 250&nbsp;mg dose of lebrikizumab, peak serum concentrations were achieved approximately 7 to 8 days post dose. The absolute bioavailability for a subcutaneous dose was estimated as 86%.</p><p>Injection site locations did not significantly influence the absorption of lebrikizumab.</p><p>Distribution</p><p>Based on a population PK analysis, the total volume of distribution at steady-state was 5.14&nbsp;L.</p><p>Metabolism/Elimination</p><p>Lebrikizumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.</p><p>In the population PK analysis, clearance was 0.154&nbsp;L/day and was independent of dose. The mean elimination half-life was 24.5&nbsp;days.</p><p>Dose Proportionality</p><p>Lebrikizumab exhibited linear pharmacokinetics with dose-proportional increase in exposure over a dose range of 37.5&nbsp;to&nbsp;500&nbsp;mg given as a subcutaneous injection in patients with AD or in healthy volunteers.</p><p>Specific Populations</p><p>Age, Sex, Race</p><p>Age, sex, or race did not have a significant effect on the pharmacokinetics of lebrikizumab.</p><p>Weight</p><p>Lebrikizumab trough concentrations were lower in subjects with higher body weight.</p><p>Patients with Renal or Hepatic Impairment</p><p>Specific clinical pharmacology studies to evaluate the effects of renal impairment and hepatic impairment on the pharmacokinetics of lebrikizumab have not been conducted. Lebrikizumab, as a monoclonal antibody, is not expected to undergo significant hepatic or renal elimination. Population pharmacokinetic analysis showed that markers of renal and hepatic function did not affect the pharmacokinetics of lebrikizumab.</p><p>Drug Interaction Studies</p><p>An effect of lebrikizumab on the PK of co-administered medications is not expected.</p><p>Immunogenicity<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_3d518dcd-5b61-4ef0-95eb-097d091ce36b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of EBGLYSS or of other drug products.</p><p>During the 12-month treatment period in EBGLYSS studies, 4/145 (2.8%) of subjects treated with 250&nbsp;mg EBGLYSS every 2 weeks followed by 250&nbsp;mg every four weeks developed antibodies to lebrikizumab, most of which were neutralizing and of low titer. Similar results were observed in adolescent subjects who received EBGLYSS up to 12&nbsp;months. The presence of anti-drug antibodies was not associated with changes to pharmacokinetics, efficacy, or safety of lebrikizumab. Because of the low occurrence of ADA, the clinical relevance of these findings is unknown.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity (including safety pharmacology endpoints) and toxicity to reproduction and development.</p><p>The mutagenic potential of lebrikizumab has not been evaluated; however monoclonal antibodies are not expected to alter DNA or chromosomes.</p><p>Carcinogenicity studies have not been conducted with lebrikizumab. Evaluation of the available evidence related to IL-13 inhibition and animal toxicology data with lebrikizumab does not suggest carcinogenic potential for lebrikizumab.</p><p>No effects on fertility parameters were observed in sexually mature monkeys after a long-term intravenous (females) or subcutaneous (males) treatment with lebrikizumab. Lebrikizumab had no effects on embryo-fetal or postnatal development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glacial acetic acid</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; L-histidine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; polysorbate 20</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sucrose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water for Injection, USP.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable for subcutaneous single-dose product. In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf Life for Autoinjector [OR Prefilled Pen]
The shelf life is 24 months [2 years] when stored at 2°C to 8°C [36°F to 46°F].

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Storage and Handling</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EBGLYSS is sterile and preservative-free.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) in the original carton to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If necessary, EBGLYSS may be kept at room temperature below 30&deg;C (86&deg;F) for up to 7 days in the original carton. Throw away EBGLYSS if not used within 7 days at room temperature.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze. Do not use EBGLYSS if it has been frozen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not shake.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discard the EBGLYSS single-dose prefilled pen after use in a puncture-resistant container.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>EBGLYSS (lebrikizumab) injection is a sterile, preservative free, clear, colorless to slightly yellow solution, free of visible particles, available in a single-dose prefilled pen. Each prefilled pen is designed to deliver 250&nbsp;mg of EBGLYSS in 2&nbsp;mL.</p><p>EBGLYSS is supplied as:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pack Size</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Prefilled Pen</strong></p></td></tr><tr><td style="vertical-align:top"><p>250&nbsp;mg/2 mL single-dose</p></td><td style="vertical-align:top"><p>Carton of 1</p></td></tr><tr><td style="vertical-align:top"><p>250&nbsp;mg/2 mL single-dose</p></td><td style="vertical-align:top"><p>Carton of 2</p></td></tr></tbody></table><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p><strong>PATIENT COUNSELING INFORMATION </strong></p><p>Advise the patient and/or caregiver to read the approved patient labeling (Package leaflet and Instructions for Use).</p><p><u>Administration Instructions</u>: Provide guidance to patients and caregivers on proper subcutaneous injection technique, including aseptic technique, and how to use the prefilled pen correctly <em>[see Posology and method of administration (4.2) and Instructions for Use].</em></p><p><u>Hypersensitivity:</u> Advise patients to discontinue EBGLYSS and to seek immediate medical attention if they experience any symptoms of systemic hypersensitivity reactions <em>[see </em><em>Special warnings and precautions for use (4.4)].</em></p><p><u>Conjunctivitis and Keratitis:</u> Advise patients to consult their healthcare provider if new onset or worsening eye symptoms develop <em>[see </em><em>Special warnings and precautions for use (4.4)].</em></p><p><u>Parasitic (Helminth) Infections:</u> Advise patients to notify their healthcare provider if they present with clinical features consistent with helminthic infection <em>[see </em><em>Special warnings and precautions for use (4.4)].</em></p><p><u>Risk of Infection with Live Vaccines:</u> Advise patients that EBGLYSS may increase the risk of infection following administration of live vaccines and that vaccination with live vaccines is not recommended during EBGLYSS treatment. Instruct patients to inform the healthcare provider that they are taking EBGLYSS prior to a potential vaccination <em>[see Warnings and Precautions (5.4)]</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eli Lilly and Company, Lilly Corporate Centre, Indianapolis, IN 46285, USA
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 August 2023
Version 1

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>